Log in to save to my catalogue

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4773904

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

About this item

Full title

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2016-01, Vol.374 (1), p.54-61

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

A resistance mutation (C1156Y) developed in a woman with anaplastic lymphoma kinase (
ALK
)-rearranged lung cancer who had a response to crizotinib. She then acquired resistance to lorlatinib. A lorlatinib resistance mutation (L1198F) led to resensitization to crizotinib.
Small-molecule tyrosine kinase inhibitors are standard therapies for...

Alternative Titles

Full title

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4773904

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4773904

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1508887

How to access this item